GlassScriptPhysician profile
Sead G Beganovic
NPI 1821080847
$7,106.48
in general payments reported to CMS, 2019-2025
50 companies · $1,672 in 2025
The $1,672 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,186 · 2020: $191 · 2021: $140 · 2022: $668 · 2023: $1,607 · 2024: $1,643 · 2025: $1,672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,759 · Education: $162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,759.30 |
| Education | $162.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $704.19 | 2019-2025 | Piqray, Kisqali |
| Janssen Biotech, INC. | $587.10 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Pfizer INC. | $568.26 | 2019-2025 | |
| Amgen INC. | $478.93 | 2019-2023 | Lumakras, Kyprolis |
| E.R. Squibb & Sons, L.L.C. | $438.00 | 2019-2025 | Opdivo, Opdualag |
| Astellas Pharma US INC | $436.85 | 2019-2025 | Padcev, Xospata, Xtandi |
| Gilead Sciences, INC. | $380.40 | 2019-2025 | Trodelvy |
| Genzyme Corporation | $340.86 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $292.49 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Celgene Corporation | $281.84 | 2019-2025 | Reblozyl, Pomalyst |
| Seagen INC. | $279.67 | 2019-2024 | Padcev |
| Abbvie INC. | $218.69 | 2022-2025 | Venclexta |
| Astrazeneca Pharmaceuticals LP | $196.37 | 2019-2025 | Enhertu |
| Eisai INC. | $148.13 | 2019-2024 | |
| Array Biopharma INC | $143.02 | 2019-2025 | Mektovi, Braftovi, Xalkori |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sead Beganovic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.